Analysts Set Insmed, Inc. (NASDAQ:INSM) Price Target at $205.52

Insmed, Inc. (NASDAQ:INSM) has earned an average rating of “Buy” from the twenty-five analysts that are currently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, twenty-two have given a buy rating and two have issued a strong buy rating on the company. The average 1-year price target among brokerages that have updated their coverage on the stock in the last year is $205.5217.

A number of research firms have recently commented on INSM. UBS Group reaffirmed a “buy” rating and set a $172.00 price objective on shares of Insmed in a research note on Friday, August 7th. BMO Capital Markets started coverage on shares of Insmed in a research note on Monday, July 20th. They set an “outperform” rating and a $192.00 price target on the stock. JPMorgan Chase & Co. decreased their price target on shares of Insmed from $179.00 to $175.00 and set an “overweight” rating on the stock in a report on Monday, August 10th. Evercore reissued an “outperform” rating and set a $170.00 price objective on shares of Insmed in a research note on Friday, August 7th. Finally, Mizuho set a $192.00 price objective on Insmed in a report on Tuesday, June 16th.

Insider Activity

In other news, COO Roger Adsett sold 239,850 shares of the business’s stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $133.27, for a total transaction of $31,964,809.50. Following the completion of the sale, the chief operating officer owned 98,744 shares in the company, valued at approximately $13,159,612.88. The trade was a 70.84% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO William Lewis sold 21,398 shares of the stock in a transaction that occurred on Thursday, June 25th. The stock was sold at an average price of $103.32, for a total transaction of $2,210,841.36. Following the sale, the chief executive officer directly owned 258,917 shares of the company’s stock, valued at approximately $26,751,304.44. This trade represents a 7.63% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 273,753 shares of company stock valued at $35,604,764 in the last three months. Corporate insiders own 2.10% of the company’s stock.

Institutional Trading of Insmed

Several institutional investors have recently added to or reduced their stakes in the stock. California State Teachers Retirement System raised its position in shares of Insmed by 10,618.8% during the 2nd quarter. California State Teachers Retirement System now owns 32,497,563 shares of the biopharmaceutical company’s stock valued at $3,464,890,000 after acquiring an additional 32,194,381 shares in the last quarter. Saudi Central Bank increased its position in Insmed by 87.1% in the second quarter. Saudi Central Bank now owns 14,732 shares of the biopharmaceutical company’s stock worth $1,571,000 after buying an additional 6,860 shares during the period. AlphaGrep UK Ltd acquired a new stake in Insmed in the second quarter worth $300,000. denkapparat Operations GmbH bought a new stake in Insmed in the second quarter valued at $207,000. Finally, AXQ Capital LP bought a new stake in Insmed in the 2nd quarter valued at about $2,432,000.

Insmed Price Performance

Insmed stock opened at $126.63 on Monday. The company has a debt-to-equity ratio of 0.74, a quick ratio of 3.40 and a current ratio of 3.72. Insmed has a one year low of $90.39 and a one year high of $212.75. The business has a fifty day moving average of $114.95 and a two-hundred day moving average of $125.37. The company has a market cap of $27.65 billion, a P/E ratio of -30.81 and a beta of 0.82.

Insmed (NASDAQ:INSM) last posted its earnings results on Thursday, August 6th. The biopharmaceutical company reported ($0.06) EPS for the quarter, topping analysts’ consensus estimates of ($0.67) by $0.61. Insmed had a negative return on equity of 123.94% and a negative net margin of 76.94%.The company had revenue of $425.49 million for the quarter, compared to the consensus estimate of $395.50 million. During the same period in the previous year, the business earned ($1.70) earnings per share. Insmed’s quarterly revenue was up 296.1% compared to the same quarter last year. As a group, analysts predict that Insmed will post -1.83 earnings per share for the current fiscal year.

About Insmed

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.